国泰海通证券股份有限公司关于宁夏中科生物科技股份有限公司详式权益变动报告书之财务顾问核查意见 国泰海通证券股份有限公司 关于 宁夏中科生物科技股份有限公司 详式权益变动报告书 之 财务顾问核查意见 财务顾问 中国（上海）自由贸易试验区商城路618号 二〇二五年十一月 1 国泰海通证券股份有限公司关于宁夏中科生物科技股份有限公司详式权益变动报告书之财务顾问核查意见 声 明 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司收购 管理办法》《公开发行证券的公司信息披露内容与格式准则第15号——权益变动 报告书》（以下简称"《15号准则》"）及《公开发行证券的公司信息披露内容 与格式准则第16号——上市公司收购报告书》（以下简称"《16号准则》"）等 法律法规和规范性文件的规定，国泰海通证券股份有限公司（以下简称"国泰海 通"或"本财务顾问"）按照行业公认的业务标准、道德规范，本着诚实信用、 勤勉尽责的精神，对本次权益变动的相关情况和资料进行了核查，对信息披露义 务人出具的《宁夏中科生物科技股份有限公司详式权益变动报告书》所披露的内 容出具核查意见，以供投资者和有关各方参考。 为此，本财务顾问特作出以下 ...

宁夏中科生物科技股份有限公司 简式权益变动报告书 宁夏中科生物科技股份有限公司 简式权益变动报告 上市公司名称：宁夏中科生物科技股份有限公司 股票上市地点：上海证券交易所 股票简称：*ST 宁科 股票代码：600165 信息披露义务人：上海中能企业发展（集团）有限公司 住所：上海市嘉定区众仁路 399 号 1 幢 B 区 609 室 通讯地址：上海市四川北路 1688 号福德大厦北楼 2008 室 权益变动性质：股份减少（执行法院裁定） 签署日期：二〇二五年十一月十七日 1 宁夏中科生物科技股份有限公司 简式权益变动报告书 声 明 一、本报告系信息披露义务人依据《中华人民共和国公司法》《中华人民共和国证券 法》《上市公司收购管理办法》《公开发行证券的公司信息披露内容与格式准则第 15 号— —权益变动报告书》及相关的法律、法规编写。 二、依据上述法律法规的规定，本报告书已全面披露了信息披露义务人在宁夏中科生 物科技股份有限公司中拥有权益的股份变动情况。 截至本报告书签署之日，除本报告书披露的信息外，上述信息披露义务人没有通过任 何其他方式增加或减少其在上市公司拥有权益的股份。 三、信息披露义务人签署本报告书已 ...

股票上市地点：上海证券交易所 股票简称：*ST 宁科 股票代码：600165 宁夏中科生物科技股份有限公司 详式权益变动报告书 宁夏中科生物科技股份有限公司 详式权益变动报告书 宁夏中科生物科技股份有限公司 详式权益变动报告书 上市公司名称：宁夏中科生物科技股份有限公司 信息披露义务人：湖南新合新生物医药有限公司 住所：常德市津市市嘉山工业新区 通讯地址：常德市津市工业园孟姜女大道 20 号 权益变动性质：股份增加（执行法院裁定） 签署日期：二〇二五年十一月 1 信息披露义务人声明 本部分所述词语或简称与本报告书"释义"所述词语或简称具有相同含义。 一、本报告书系信息披露义务人依据《公司法》《证券法》《收购管理办法》 《公开发行证券的公司信息披露内容与格式准则第 15 号—权益变动报告书》《公 开发行证券的公司信息披露内容与格式准则第 16 号—上市公司收购报告书》及 相关的法律、法规编制。 二、依据《证券法》《收购管理办法》《公开发行证券的公司信息披露内容与 格式准则第 15 号—权益变动报告书》《公开发行证券的公司信息披露内容与格式 准则第 16 号—上市公司收购报告书》的规定，本报告书已全面披露信息披露 ...

Core Viewpoint - The announcement from *ST Ningke indicates that the execution of the restructuring plan will lead to a change in the controlling shareholder and actual controller of the company [1] Summary by Relevant Sections Shareholder Changes - The company will implement a capital reserve increase by converting 6.85 billion shares, resulting in an increase of 13.593 shares for every 10 shares held, raising the total share capital to 1.616 billion shares [1] - After the equity change, Hunan Xinhong will hold 357 million shares, representing 22.10% of the total shares, thus becoming the controlling shareholder, while Liu Xirong will become the actual controller [1] - The original controlling shareholder, Shanghai Zhongneng, will see its shareholding decrease to 12.38% [1] Risks - If the company fails to execute or cannot execute the restructuring plan, there is a risk of being declared bankrupt and delisted [1]

Core Viewpoint - The announcement details the progress of the second judicial auction of shares held by the controlling shareholder of Ningxia Zhongke Biotechnology Co., Ltd., indicating that the shares have been auctioned and the outcome is pending further legal procedures [2][4]. Group 1: Shareholding and Auction Details - Shanghai Zhongneng Enterprise Development (Group) Co., Ltd. holds 200,000,000 shares of Ningxia Zhongke, accounting for 29.20% of the total share capital, with all shares pledged and frozen [2][3]. - The second judicial auction for the 200,000,000 shares took place from November 17 to November 18, 2025, on the JD Network Judicial Auction platform [4][5]. - The auction results indicate that the shares were successfully bid on, with the final transaction subject to the court's auction ruling [5][6]. Group 2: Future Steps and Uncertainties - Following the auction, there are still steps involving the payment of auction proceeds, legal execution procedures, and the transfer of share ownership, which introduces uncertainty regarding the final outcome [2][6]. - If the shares are fully transferred, Shanghai Zhongneng will no longer hold any shares in the company [2][6]. - The company will closely monitor the situation and fulfill its information disclosure obligations as required by relevant laws and regulations [2][6].

证券代码：600165 股票简称：*ST 宁科 公告编号：临 2025-120 宁夏中科生物科技股份有限公司 关于控股股东股份被第二次司法拍卖的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 截至本公告披露日，上海中能企业发展（集团）有限公司（以下简称： 上海中能）持有宁夏中科生物科技股份有限公司（以下简称：公司）股份 200,000,000 股，占公司总股本的 29.20%。上海中能质押股份数为 200,000,000 股，且已被冻结，占其持有公司股份总数的 100%。 ● 第二次司法拍卖网拍阶段已结束，拍卖股份竞买成交 200,000,000 股，占 上海中能持有公司股份总数的 100%，占公司总股本的 29.20%。拍卖标的最 终成交以广东省广州市中级人民法院出具的拍卖成交裁定为准。后续仍涉及缴 纳竞拍余款、法院执行法定程序、股权变更过户等环节，最终结果存在一定的 不确定性。若上述拍卖股份全部完成过户登记后，上海中能将不再持有公司股 份。 ● 公司将密切关注上述事项的后续进展情况，并根据相关 ...

Group 1 - The controlling shareholder, Shanghai Zhongneng, holds 200 million shares of Ningxia Zhongke Biological, accounting for 29.20% of the total share capital, and all shares are pledged and frozen [1] - A second judicial auction concluded with all 200 million shares successfully sold, with a total transaction amount of 639 million yuan, involving seven bidders [1] - The final transaction will be subject to court ruling, and there is uncertainty regarding the completion of the transfer process, which includes payment of the remaining amount and legal procedures [1] Group 2 - If the transfer is completed, Shanghai Zhongneng will no longer hold shares, and the acquirer is prohibited from reducing their holdings within six months [1]

Core Points - The Shanghai Composite Index closed at 3939.81 points, above the six-month moving average, with a decline of 0.81% [1] - The total trading volume of A-shares reached 1,945.96 billion yuan [1] - A total of 51 A-shares have surpassed the six-month moving average, with notable stocks showing significant deviation rates [1] Summary by Category Market Performance - The Shanghai Composite Index is currently at 3939.81 points, indicating a slight decline of 0.81% [1] - The total trading volume for A-shares today was 1,945.96 billion yuan [1] Stocks Surpassing Six-Month Moving Average - 51 A-shares have broken through the six-month moving average, with the highest deviation rates observed in: - Longxun Co., Ltd. with a deviation rate of 18.63% and a price increase of 20.00% [1] - Meideng Technology with a deviation rate of 14.56% and a price increase of 22.82% [1] - Jingchen Co., Ltd. with a deviation rate of 9.04% and a price increase of 11.90% [1] Additional Notable Stocks - Other stocks with significant performance include: - Guangyun Technology with a deviation rate of 8.67% and a price increase of 19.99% [1] - Qixin Group with a deviation rate of 8.30% and a price increase of 10.07% [1] - Haohan Deep Technology with a deviation rate of 6.70% and a price increase of 9.03% [1]

Core Viewpoint - *ST Ningke (600165.SH) and its subsidiaries have received court approval for their restructuring plans, marking a significant step in their financial recovery process [1] Group 1: Company Restructuring - The company and its subsidiaries, Ningxia Zhongke Biological New Materials Co., Ltd. and Ningxia Xinhai Hengli International Trade Co., Ltd., have been granted approval for their respective restructuring plans by the Shizuishan Intermediate People's Court [1] - The court's decision includes the termination of the restructuring procedures for the company and its subsidiaries, indicating a potential stabilization in their operations [1]

Core Viewpoint - *ST Ningke (600165.SH) and its subsidiaries have received court approvals for their restructuring plans, marking the end of their restructuring processes [1] Group 1 - The company and its subsidiaries, Ningxia Zhongke Biological New Materials Co., Ltd. and Ningxia Xinhai Hengli International Trade Co., Ltd., received civil rulings from the Intermediate People's Court of Shizuishan, Ningxia Hui Autonomous Region [1] - The court approved the restructuring plans for Ningxia Zhongke Biotechnology Co., Ltd., Ningxia Zhongke Biological New Materials Co., Ltd., and Ningxia Xinhai Hengli International Trade Co., Ltd. [1] - The restructuring procedures for the company and its subsidiaries have been terminated following the court's decision [1]